Effect of evolocumab on atherogenic lipoproteins during the peri- And early postinfarction period: A placebo-controlled, randomized trial

Thorsten M. Leucker; Michael J. Blaha; Steven R. Jones; Michael A. Vavuranakis; Marlene S. Williams; Hong Lai; Thomas H. Schindler; Jacqueline Latina; Steven P. Schulman; Gary Gerstenblith

doi:10.1161/CIRCULATIONAHA.120.046320

Effect of evolocumab on atherogenic lipoproteins during the peri- And early postinfarction period: A placebo-controlled, randomized trial

Thorsten M. Leucker, Michael J. Blaha, Steven R. Jones, Michael A. Vavuranakis, Marlene S. Williams, Hong Lai, Thomas H. Schindler, Jacqueline Latina, Steven P. Schulman, Gary Gerstenblith

Division of Nuclear Medicine

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Original language	English
Pages (from-to)	419-421
Number of pages	3
Journal	Circulation
Volume	142
Issue number	4
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.120.046320
State	Published - Jul 28 2020

Keywords

acute coronary syndrome
cholesterol, LDL
evolocumab
secondary prevention

Access to Document

10.1161/CIRCULATIONAHA.120.046320

Cite this

Leucker, T. M., Blaha, M. J., Jones, S. R., Vavuranakis, M. A., Williams, M. S., Lai, H., Schindler, T. H., Latina, J., Schulman, S. P., & Gerstenblith, G. (2020). Effect of evolocumab on atherogenic lipoproteins during the peri- And early postinfarction period: A placebo-controlled, randomized trial. Circulation, 142(4), 419-421. https://doi.org/10.1161/CIRCULATIONAHA.120.046320

@article{5b133e723b134e9690010463fcdbf847,

title = "Effect of evolocumab on atherogenic lipoproteins during the peri- And early postinfarction period: A placebo-controlled, randomized trial",

keywords = "acute coronary syndrome, cholesterol, LDL, evolocumab, secondary prevention",

author = "Leucker, {Thorsten M.} and Blaha, {Michael J.} and Jones, {Steven R.} and Vavuranakis, {Michael A.} and Williams, {Marlene S.} and Hong Lai and Schindler, {Thomas H.} and Jacqueline Latina and Schulman, {Steven P.} and Gary Gerstenblith",

note = "Funding Information: Dr Leucker has received grants from American Heart Association Career Development Award, National Institutes of Health, and Amgen. Dr Blaha has received grants from the National Instititues of Health, FDA, AHA, Amgen, and Aetna; and is on the advisory board for Novo Nordisk, Bayer, Novartis, Amgen, Sanofi, Regeneron, and Akcea. Dr Vavuranakis has received grants from the National Institutes of Health. Dr Williams is on the scientific advisory board of Haemonet-ics; the Steering Committee for CME on DAPT–University of North Texas and Rockpointe; and is supported by an educational grant from Astra Zeneca. Dr Schindler has received grants from GE Healthcare Research study (F-Flurpirdaz Perfusion PET study - phase 3 clinical trial). Dr Gerstenblith has received grants from the National Institutes of Health. The other authors report no conflicts.",

year = "2020",

month = jul,

day = "28",

doi = "10.1161/CIRCULATIONAHA.120.046320",

language = "English",

volume = "142",

pages = "419--421",

journal = "Circulation",

issn = "0009-7322",

number = "4",

}

Leucker, TM, Blaha, MJ, Jones, SR, Vavuranakis, MA, Williams, MS, Lai, H, Schindler, TH, Latina, J, Schulman, SP & Gerstenblith, G 2020, 'Effect of evolocumab on atherogenic lipoproteins during the peri- And early postinfarction period: A placebo-controlled, randomized trial', Circulation, vol. 142, no. 4, pp. 419-421. https://doi.org/10.1161/CIRCULATIONAHA.120.046320

TY - JOUR

T1 - Effect of evolocumab on atherogenic lipoproteins during the peri- And early postinfarction period

T2 - A placebo-controlled, randomized trial

AU - Leucker, Thorsten M.

AU - Blaha, Michael J.

AU - Jones, Steven R.

AU - Vavuranakis, Michael A.

AU - Williams, Marlene S.

AU - Lai, Hong

AU - Schindler, Thomas H.

AU - Latina, Jacqueline

AU - Schulman, Steven P.

AU - Gerstenblith, Gary

N1 - Funding Information: Dr Leucker has received grants from American Heart Association Career Development Award, National Institutes of Health, and Amgen. Dr Blaha has received grants from the National Instititues of Health, FDA, AHA, Amgen, and Aetna; and is on the advisory board for Novo Nordisk, Bayer, Novartis, Amgen, Sanofi, Regeneron, and Akcea. Dr Vavuranakis has received grants from the National Institutes of Health. Dr Williams is on the scientific advisory board of Haemonet-ics; the Steering Committee for CME on DAPT–University of North Texas and Rockpointe; and is supported by an educational grant from Astra Zeneca. Dr Schindler has received grants from GE Healthcare Research study (F-Flurpirdaz Perfusion PET study - phase 3 clinical trial). Dr Gerstenblith has received grants from the National Institutes of Health. The other authors report no conflicts.

PY - 2020/7/28

Y1 - 2020/7/28

KW - acute coronary syndrome

KW - cholesterol, LDL

KW - evolocumab

KW - secondary prevention

UR - http://www.scopus.com/inward/record.url?scp=85088811109&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.120.046320

DO - 10.1161/CIRCULATIONAHA.120.046320

M3 - Letter

C2 - 32718248

AN - SCOPUS:85088811109

VL - 142

SP - 419

EP - 421

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 4

ER -

Effect of evolocumab on atherogenic lipoproteins during the peri- And early postinfarction period: A placebo-controlled, randomized trial

Keywords

Access to Document

Other files and links

Cite this